---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-020424"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:21:36.940217+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corbus CRB-701 Phase 1 Western data: low neuropathy, HNSCC responses, dose optimization started

## Summary
- No DLTs; peripheral neuropathy 5% (Grade 1-2) vs 3% in China; combined 4% across 75 patients.
- Ocular AEs lower in Western study (38% vs 66%) with proactive prevention protocol at 2.7/3.6 mg/kg.
- Efficacy: 4 PR in HNSCC (n=7); 1 CR in cervical; mUC responses despite prior EV treatment.
- PK comparable to China; CRB-701 shows longer ADC half-life and lower free-MMAE vs enfortumab vedotin.
- Dose optimization randomized at 2.7 and 3.6 mg/kg Q3W in HNSCC, cervical, and mUC cohorts.

## SEC filing metadata
- accession: 0000950170-25-020424
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017025020424/0000950170-25-020424-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017025020424/crbp-20250214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-020424
- JSON: https://secwatch.observer/filing/0000950170-25-020424.json
- Plain text: https://secwatch.observer/filing/0000950170-25-020424.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.